These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 10994564)

  • 41. NSAID induced gastrointestinal complications: the ARAMIS perspective--1997. Arthritis, Rheumatism, and Aging Medical Information System.
    Singh G; Rosen Ramey D
    J Rheumatol Suppl; 1998 May; 51():8-16. PubMed ID: 9596549
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Gastrointestinal side effects of non-steroidal anti-inflammatory agents and costs in the National Health System].
    Lanas A
    An Med Interna; 2001 Nov; 18(11):561-3. PubMed ID: 11862764
    [No Abstract]   [Full Text] [Related]  

  • 43. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy.
    Wolfe F; Anderson J; Burke TA; Arguelles LM; Pettitt D
    J Rheumatol; 2002 Mar; 29(3):467-73. PubMed ID: 11908558
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Gastrointestinal side-effects of traditional non-steroidal anti-inflammatory drugs and new formulations.
    Lazzaroni M; Bianchi Porro G
    Aliment Pharmacol Ther; 2004 Jul; 20 Suppl 2():48-58. PubMed ID: 15335413
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice.
    Moore RA; Derry S; Phillips CJ; McQuay HJ
    BMC Musculoskelet Disord; 2006 Oct; 7():79. PubMed ID: 17054784
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [The lack of awareness of the Israeli population regarding gastrointestinal complications from non-steroidal anti-inflammatory drugs].
    Zandman-Goddard G; Langevitz P
    Harefuah; 2001 Jun; 140(6):476-8, 567, 566. PubMed ID: 11420844
    [TBL] [Abstract][Full Text] [Related]  

  • 48. GI risk factors and use of GI protective agents among patients receiving nonsteroidal antiinflammatory drugs.
    Harris CL; Raisch DW; Abhyankar U; Marfatia S; Campbell HM; Sather MR
    Ann Pharmacother; 2006 Nov; 40(11):1924-31. PubMed ID: 17047140
    [TBL] [Abstract][Full Text] [Related]  

  • 49. NSAIDs-induced gastrointestinal damage. Review.
    Arroyo M; Lanas A
    Minerva Gastroenterol Dietol; 2006 Sep; 52(3):249-59. PubMed ID: 16971869
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The iatrogenic costs of NSAID therapy: a population study.
    Sturkenboom MC; Romano F; Simon G; Correa-Leite ML; Villa M; Nicolosi A; Borgnolo G; Bianchi-Porro G; Mannino S
    Arthritis Rheum; 2002 Apr; 47(2):132-40. PubMed ID: 11954006
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost of prescribed NSAID-related gastrointestinal adverse events in elderly patients.
    Rahme E; Joseph L; Kong SX; Watson DJ; LeLorier J
    Br J Clin Pharmacol; 2001 Aug; 52(2):185-92. PubMed ID: 11488776
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Minimizing the costs of prescription of anti-infective drugs in two areas of primary health care].
    Castán Cameo S; García Latorre FJ; Martínez Gorostiaga J; Sierra Moros MJ; Solano Bernad VM; Peral Casado A
    Rev Esp Salud Publica; 1998; 72(1):33-42. PubMed ID: 9477714
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Excess costs related to non-steroidal anti-inflammatory drug utilization in general practice.
    Moore N; Verschuren X; Montout C; Callens J; Kong SX; Bégaud B
    Therapie; 2000; 55(1):133-6. PubMed ID: 10860014
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Economic evaluation of the restriction in the use piroxicam in Spain.
    Maciá Martínez MÁ
    Reumatol Clin; 2015; 11(6):345-52. PubMed ID: 25636384
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Upper gastrointestinal symptoms in patients treated with nonsteroidal anti-inflammatory drugs: prevalence and impact--the COMPLAINS study.
    Thiéfin G; Schaeverbeke T; Barthélémy P; Soufflet C; Flipo RM
    Eur J Gastroenterol Hepatol; 2010 Jan; 22(1):81-7. PubMed ID: 19654549
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Gastrointestinal complications of nonsteroidal anti-inflammatory drugs.
    Babb RR
    West J Med; 1992 Oct; 157(4):444-7. PubMed ID: 1462539
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The economic consequences of NSAID-induced gastropathy: the French context.
    de Pouvourville G
    Scand J Rheumatol Suppl; 1992; 96():49-53. PubMed ID: 1439624
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Analysis of the costs of NSAID-associated gastropathy. Experience in a US health maintenance organisation.
    Johnson RE; Hornbrook MC; Hooker RS; Woodson GT; Shneidman R
    Pharmacoeconomics; 1997 Jul; 12(1):76-88. PubMed ID: 10169389
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Management of chronic non-terminal renal failure in childhood. Estimation of mean annual cost].
    Orejas Rodríguez-Arango G; Málaga Guerrero S; Santos Rodríguez F; Martínez Gonzáles I; Rodríguez Fernández LM; Rey Galán C
    An Esp Pediatr; 1990 Oct; 33(4):335-8. PubMed ID: 2278434
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Healthcare resource utilisation and costs of treating NSAID-associated gastrointestinal toxicity. A multinational perspective.
    Chevat C; Peña BM; Al MJ; Rutten FF
    Pharmacoeconomics; 2001; 19 Suppl 1():17-32. PubMed ID: 11280103
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.